GlassScriptPhysician profile
Laura E Divoky
NPI 1336439991
$5,022.93
in general payments reported to CMS, 2019-2025
28 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $336 · 2021: $388 · 2022: $736 · 2023: $743 · 2024: $1,310 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,081.08 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $662.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $519.64 | 2022-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $478.92 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $460.60 | 2021-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $451.50 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $202.65 | 2021-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.83 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $110.57 | 2020-2025 | Farxiga, Wainua |
| Actelion Pharmaceuticals US, INC. | $100.22 | 2020-2025 | Uptravi, Opsumit |
| Bridgebio Pharma, INC. | $83.18 | 2025 | Attruby |
| Ionis Pharmaceuticals, INC. | $79.04 | 2025 | Tryngolza |
| Sanofi-Aventis U.S. LLC | $73.88 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $70.55 | 2023-2024 | Evkeeza |
| Heartflow, INC. | $65.66 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.43 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $59.82 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $56.85 | 2021-2024 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $56.20 | 2021-2023 | Injectafer |
| Baxter Healthcare | $46.57 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Amarin Pharma, INC. | $31.21 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.96 | 2024-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $24.51 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Alnylam Pharmaceuticals INC. | $24.41 | 2024 | Amvuttra |
| Esperion Therapeutics, INC. | $24.34 | 2023 | Nexletol |
| Abiomed | $18.50 | 2025 | |
| Irhythm Technologies, INC. | $14.29 | 2023 | Zio Xt Patch |
| Philips North America LLC | $14.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Divoky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.